ITGAV and pancreatic adenocarcinoma: Similar to in SCLC, ITGAV expression showed significantly distinctive effects between cancers and non-cancers, particularly for cholangiocarcinoma, esophageal carcinoma, glioblastoma multiforme, glioma, acute myeloid leukemia, LGG, PAAD, and high-risk Wilms tumors (all AUCs > 0.9; Fig. 7).